Clearside Biomedical
在场
Clearside Biomedical 是一家在股票代码 CLSD (US) 下上市的公司。
高管
查看带有其 18 名主要高管的组织结构图
Clearside Biomedical 搜索最多的简介
- George Lasezkay, Chief Executive Officer and Director
- William Humphries, Director
- Clay Thorp, Director
高管在Clearside Biomedical变化
- Anthony Gibney 曾任 Director, 现升职为 Chairman of the Board (新闻发布的2024十一月5号).
- Anthony Gibney已作为Director加入公司 (新闻发布的2024四月17号).
创建提醒
跟踪 Clearside Biomedical 的高管变动
生物技术
Clearside Biomedical 拥有 2,335 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Visus Therapeutics and Tenpoint Therapeutics have merged (公布2024十二月27号)..
- Deerfield has announced the acquisition of Singular Genomics (公布2024十二月24号).
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
Clearside Biomedical 的最新新闻稿
- Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE™ Data in Diabetic Macular Edema in Ophthalmology Retina | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal Delivery | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical to Present at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical’s Licensing Partner Doses First Patient in its Phase 2 Gene Therapy Trial Using SCS Microinjector® for Suprachoroidal Delivery | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Expands Patent Portfolio in the U.S. and Europe | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate Update | Clearside Biomedical, Inc.- IR Site
- View more press releases Close
通过电子邮件
